Different Survival Benefits of Chinese Medicine for Pancreatic Cancer: How to Choose?

Overview

Journal Chin J Integr Med

Date 2017 Oct 25

PMID 29063468

Citations 7

Authors

Meng Li

Miao-Miao Wang

Xiu-Wei Guo

Chao-Yong Wu

Dao-Rui Li

Xing Zhang

Pei-Tong Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: To assess the efficacy of Chinese medicine (CM) on patients with pancreatic cancer (PC) in a retrospective population-based study.

Methods: Between January 1, 2013, and August 30, 2016, according to whether received Western medicine treatment, the patients were included into either integrative medicine (IM) group or CM group. All enrolled patients were orally administrated with Gexia Zhuyu Decoction () or Liujun Ermu Decoction () by syndrome differentiation, twice a day, last for at least 2 months. The primary end point was overall survival (OS).

Results: A total of 174 patients with PC were enrolled in this study. In stage I/II, the median OS was 20.5 months in the IM group [95% confidence interval (CI), 12.499 to 28.501] and 11.17 months in the CM group (95% CI, 5.160 to 17.180, P=0.015). The 1- and 2-year survival rates for the two groups were 47.0%, 40.0% and 21.0%, 21.0%, respectively. In stage III/IV, median OS was 13.53 months (95% CI, 8.665 to 18.395) in the IM group versus 6.4 months (95% CI, 0.00 to 15.682) in the CM group, respectively (P=0.32). The 1- and 2-year survival rate for the IM and CM groups were 27.0%, 7.0% and 20.0%, 2.0%, respectively.

Conclusions: Intervention of CM contributes to the different survival benefits for PC in different stages. Multimodality treatment might be a promising strategy for PC patients in early stage. While, in advanced stage, CM might be an alternative candidate for PC patients.

Citing Articles

Network pharmacology‑based analysis and experimental verification of the inhibitory role of luteoloside on gastric cancer cells via the p53/p21 pathway.

Lin X, Yang P, Li X, Xu Z, Wu H, Hu S Oncol Lett. 2024; 29(2):76.

PMID: 39650229 PMC: 11622105. DOI: 10.3892/ol.2024.14822.

Research progress in the establishment of pancreatic cancer models and preclinical applications.

Wu W, Wen K, Zhong Y Cancer Innov. 2023; 1(3):207-219.

PMID: 38089760 PMC: 10686130. DOI: 10.1002/cai2.31.

Advances in the treatment of pancreatic cancer with traditional Chinese medicine.

Zhang Y, Xu H, Li Y, Sun Y, Peng X Front Pharmacol. 2023; 14:1089245.

PMID: 37608897 PMC: 10440824. DOI: 10.3389/fphar.2023.1089245.

Pharmacological Mechanisms Underlying the Hepatoprotective Effects of on Hepatocellular Carcinoma.

Pan B, Pan W, Lu Z, Xia C Evid Based Complement Alternat Med. 2021; 2021:5591402.

PMID: 34326886 PMC: 8302389. DOI: 10.1155/2021/5591402.

Study on the treatment of pancreatic cancer with integrated traditional Chinese and Western medicine: A study protocol of a multicenter prospective cohort study.

Jiang J, Liu R, Zhang Z, Zhang X, Qi R, Chen S Medicine (Baltimore). 2019; 98(47):e17975.

PMID: 31764804 PMC: 6882619. DOI: 10.1097/MD.0000000000017975.

References

Wagner M, Dikopoulos N, Kulli C, Friess H, Buchler M . Standard surgical treatment in pancreatic cancer. Ann Oncol. 1999; 10 Suppl 4:247-51. View

Lin S, Xu J, Ji X, Chen H, Xu H, Hu P . Emodin inhibits angiogenesis in pancreatic cancer by regulating the transforming growth factor-β/drosophila mothers against decapentaplegic pathway and angiogenesis-associated microRNAs. Mol Med Rep. 2015; 12(4):5865-71. DOI: 10.3892/mmr.2015.4158. View

Yang G, Wagner T, Fuss M, Thomas Jr C . Multimodality approaches for pancreatic cancer. CA Cancer J Clin. 2005; 55(6):352-67. DOI: 10.3322/canjclin.55.6.352. View

Xu L, Li H, Xu Z, Wang Z, Liu L, Tian J . Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients. BMC Complement Altern Med. 2012; 12:112. PMC: 3502343. DOI: 10.1186/1472-6882-12-112. View

Xu Y, Zhao A, Li Z, Zhao G, Cai Y, Zhu X . Survival benefit of traditional Chinese herbal medicine (a herbal formula for invigorating spleen) for patients with advanced gastric cancer. Integr Cancer Ther. 2012; 12(5):414-22. DOI: 10.1177/1534735412450512. View

Colucci G, Labianca R, Di Costanzo F, Gebbia V, Carteni G, Massidda B . Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010; 28(10):1645-51. DOI: 10.1200/JCO.2009.25.4433. View

Hidalgo M . Pancreatic cancer. N Engl J Med. 2010; 362(17):1605-17. DOI: 10.1056/NEJMra0901557. View

Xu Y, Zhu F, Xu S, Liu L . Anti-tumor effect of the extract from qingyihuaji formula on pancreatic cancer by down-regulating Notch-4 and Jagged-1. J Tradit Chin Med. 2015; 35(1):77-83. DOI: 10.1016/s0254-6272(15)30012-1. View

Zhou Z, Zhang C, Fei H, Zhong L, Bai Y . Phenolic alkaloids from Menispermum dauricum inhibits BxPC-3 pancreatic cancer cells by blocking of Hedgehog signaling pathway. Pharmacogn Mag. 2015; 11(44):690-7. PMC: 4621636. DOI: 10.4103/0973-1296.165548. View

10.

Von Hoff D, Ervin T, Arena F, Chiorean E, Infante J, Moore M . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. PMC: 4631139. DOI: 10.1056/NEJMoa1304369. View

11.

Pan F, Zhou H, Bu H, Chen Z, Zhang H, Xu L . Emodin enhances the demethylation by 5-Aza-CdR of pancreatic cancer cell tumor-suppressor genes P16, RASSF1A and ppENK. Oncol Rep. 2016; 35(4):1941-9. PMC: 4774670. DOI: 10.3892/or.2016.4554. View

12.

Johnston W, Hoen H, Cassera M, Newell P, Hammill C, Hansen P . Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base. HPB (Oxford). 2016; 18(1):21-8. PMC: 4750230. DOI: 10.1016/j.hpb.2015.07.009. View

13.

Ioka T, Okusaka T, Ohkawa S, Boku N, Sawaki A, Fujii Y . Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial. Jpn J Clin Oncol. 2015; 45(5):439-48. PMC: 4412139. DOI: 10.1093/jjco/hyv011. View

14.

Goncalves A, Gilabert M, Francois E, Dahan L, Perrier H, Lamy R . BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 2012; 23(11):2799-2805. DOI: 10.1093/annonc/mds135. View

15.

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

16.

Liu Y, Zhang W, Wang X, Liu S . Antitumor effect of Kanglaite® injection in human pancreatic cancer xenografts. BMC Complement Altern Med. 2014; 14:228. PMC: 4105135. DOI: 10.1186/1472-6882-14-228. View

17.

Zafar S, El-Rayes B . Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2012; 37(2):194-200. DOI: 10.1097/COC.0b013e318248d8bb. View

18.

Neoptolemos J, Stocken D, Bassi C, Ghaneh P, Cunningham D, Goldstein D . Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010; 304(10):1073-81. DOI: 10.1001/jama.2010.1275. View

19.

Nentwich M, Konig A, Izbicki J . Limits of surgery for pancreatic cancer. Rozhl Chir. 2014; 93(9):445-9. View

20.

Oettle H, Neuhaus P, Hochhaus A, Hartmann J, Gellert K, Ridwelski K . Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310(14):1473-81. DOI: 10.1001/jama.2013.279201. View